Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
Authors:
- Emil NovruzovEmil Novruzov
- Frederik L. GieselFrederik L. Giesel
- Yuriko MoriYMYuriko Mori
- Peter L. ChoykePCPeter L. Choyke
- Mardjan DabirMDMardjan Dabir
- Eduards MamlinsEMEduards Mamlins
- Dominik SchmittDSDominik Schmitt
- Christina AntkeCAChristina Antke
- Claudio PintoCPClaudio Pinto
- Cristian Soza-RiedCSCristian Soza-Ried
- Rene FernandezRFRene Fernandez
- Horacio AmaralHAHoracio Amaral
Open Access
Abstract
Background: Radiolabeled fibroblast activation protein (FAP) ligands, a novel class of tracers for PET/CT imaging, have demonstrated very promising results in various oncological, as well as in some benign, diseases with long-term potential to supplant the current pan-cancer agent [18F]FDG in some cancer types. Pancreatic ductal carcinoma (PDAC) belongs to the group of epithelial malignancies with a strong so-called “desmoplastic reaction”, leading to a prominent tumor stroma with cancer-associated fibroblasts that exhibit a marked overexpression of fibroblast activation protein (FAP). The first clinical experiences in PDAC with 68Ga-labeled FAP ligands suggested superior sensitivity to [18F]FDG. However, there is limited data with 18F-labeled FAP derivatives, i.e. [18F]FAPI-74, yet prospective single- and multicenter trials are already ongoing. In this proof-of-concept study, we sought to evaluate the biodistribution, tumor uptake, and lesion detectability in patients with PDAC using [18F]FAPI-74 PET/CT as compared to [18F]FDG PET/CT scans for staging. Methods: This study includes 7 patients (median age 69) who underwent both [18F]FDG PET/CT with contrast-enhancement and [18F]FAPI-74 PET with low-dose CT for primary staging (n = 3) and therapy response control after neoadjuvant (n = 1) or re-staging after palliative therapy (n = 3). The mean interval between PET scans was 11 ± 4 days (range 1–15 days). The [18F]FDG and [18F]FAPI-74 PET/CT scans were acquired at 64 ± 4.1 min (range 61–91 min) and 66.4 ± 6.3 min (range 60–76 min), respectively, after administration of 200 ± 94 MBq (range 79–318 MBq) and 235 ± 88 MBq (range 90–321 MBq), respectively. Quantification of tracer uptake was determined with SUVmax and SUVmean. Furthermore, the tumor-to-background ratio (TBR) was derived by dividing the SUVmax of tumor lesions by the SUVmax of adipose tissue, skeletal muscle, and blood pool. Results: Overall, 32 lesions were detected in 7 patients including primary (n = 7), lung (n = 7), bone (n = 3), lymph node (n = 13), and peritoneal metastases (n = 2). [18F]FAPI-74 detected 22% more lesions compared with [18F]FDG with a better TBR and visual lesion delineation. In one patient the primary lesion could be detected unequivocally with [18F]FAPI-74 but was missed by [18F]FDG imaging. Altogether, most of the lesions demonstrated markedly elevated uptake of [18F]FAPI-74 with a simultaneous lower uptake in the background, providing a very high visual contrast. Conclusion: To the best of our knowledge, this is the first, prospective, intra-individual investigation comparing [18F]FAPI-74 with [18F]FDG imaging in PDAC with encouraging results. These pivotalresults supporta larger, multicentric, prospective study to determine the value of [18F]FAPI-74 in detecting and staging PDAC in comparison with current standard of care imaging.Keywords
This publication has 32 references indexed in Scilit:
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of CancerJournal of Nuclear Medicine, 2019
- The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysisEuropean Journal of Radiology, 2018
- 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various CancersJournal of Nuclear Medicine, 2018
- Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation ProteinJournal of Nuclear Medicine, 2018
- A Tumor-Imaging Method Targeting Cancer-Associated FibroblastsJournal of Nuclear Medicine, 2018
- Targeting cancer cell metabolism in pancreatic adenocarcinomaOncotarget, 2015
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significanceWorld Journal of Gastroenterology, 2012
- Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: A meta-analysisEuropean Journal of Radiology, 2011
- Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein αJournal of Biological Chemistry, 2005